JSPR

Jasper Therapeutics, Inc. (JSPR) | Rumor.io

Jasper Therapeutics

JSPR

Attention (50-day avg)0%

Attention rank (50-day avg)#2,548

Bullish sentiment (50-day avg)1%

Price to earnings ratio-0.16

Market capitalization20.8M

Earnings per share-0.96

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-75.8M

Social

What share of all stock conversation is about JSPR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% +0	0% 0

Jul 17

Jasper Therapeutics has announced a merger with Kira Pharmaceuticals, combining their clinical pipelines and development resources, and is expected to be supported by a planned private placement of approximately $132 million.
The merger has been completed, and the combined company will continue trading on Nasdaq as JSPR, with common stock holders receiving a CVR worth around $1.5 payable when they receive a PRV by December 31, 2028.
Jasper's briquilimab, a potential treatment for SCID, may differentiate the company from Celldex's current indications, and the company plans to focus on other assets for now, with data expected at the end of the year.

Generated by AI

Sentiment

Of the messages about JSPR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% -100	52.87% -23.64
Bearish	—	—	100% new	47.13% +23.64

Bullish· Jul 17

The company has a strong pipeline, with three drug candidates and data expected end of year, which could lead to a significant increase in value.
The acquisition of Kira Pharma has extended the company's cash runway into 2028, providing a safety net and reducing the risk of future dilution.
The company's science and research are showing great promise, with a potential payout of $1.5 per share in 2028 and a new drug in phase 3, which could lead to a significant increase in value.

Bearish· Dec 3

The company's share price has experienced significant price destruction, with some users suggesting it's one of the "shittiest biotechs of all time".
The company's financial situation is uncertain, with some users expressing concern about dilution and the company's ability to raise more cash.
The company's product development is facing challenges, with some users questioning the effectiveness of their drug and suggesting the company is "incinerating investors".

Generated by AI

Topics

Of the messages about JSPR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	73.88%
Technical Analysis	—	—	—	11.42%
Analysts	—	—	—	7.79%
Controversies	—	—	—	0.87%
Earnings	—	—	—	2.6%
Macro	—	—	—	3.46%

Analysts· Oct 13

Oppenheimer analyst Jay Olson initiates coverage on Jasper Therapeutics with an Outperform rating and announces a price target of $21, viewing the company as an emerging leader in the development of novel targeted conditioning agents.
The analysts at Oppenheimer initiated coverage of Jasper Therapeutics with an Outperform rating and a $21 price target, citing the company's potential in hematopoietic stem cell transplantation.
Jasper Therapeutics shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target, implying a further 41% gain from current levels.

Announcements· Dec 2

Jasper Therapeutics ($JSPR) reports positive preliminary data from the ETESIAN study of Briquilimab in asthma, showing reductions in airway hyperresponsiveness and sputum eosinophils.
The company completed an internal investigation of the BEACON study with no issues found in the drug product, supporting further development of Briquilimab in asthma.
Jasper Therapeutics plans to host a conference call and webinar to discuss the positive preliminary data from the ETESIAN study and the findings from the BEACON study internal investigation.

Technical Analysis· Jan 13

$JSPR broke out higher after a pullback, reaching a high of $2.85 before selling off to flat.
The stock has resistance at $2.28 and $2.34, and may make a run if it can clear these levels.
$JSPR has a bullish reversal doji on the chart, and may be setting up for a cup and handle formation.

Generated by AI

Community

Of the messages about JSPR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	12.37%	38.45%
Newcomers	—	0%	87.63%	61.55%

Regulars· Jul 17

Jasper Therapeutics has finalized an all-stock acquisition of Kira Pharmaceuticals, establishing a robust immunology-focused biologics pipeline.
The company's strategic move is expected to extend its cash runway through 2028, with no more risk for cash until then, which is considered great.
Buyers are treating every pause in the stock's price as temporary, and the implied value for JSPR is around $0.70 per share, with the current price at $0.90.

Newcomers· Jul 17

The merger between Jasper Therapeutics and Kira Pharmaceuticals is expected to be supported by a private placement of approximately $132M via non-voting convertible preferred stock.
The combined company will trade on Nasdaq as JSPR, and common stock holders will receive a CVR worth around $1.5 payable when they receive a PRV by December 31, 2028.
Jasper Therapeutics has three drug candidates in development, with data expected at the end of the year, which may lead to a stock price surge.

Generated by AI

News

Jasper Therapeutics Announces Key Regulatory and Clinical Appointments

Lisa Pitt, Pharm.D., M.S.J. appointed Senior Vice President, Regulatory Affairs Shiguang Liu, M.D., Ph.D. appointed Vice President, Clinical Development REDWOOD CITY, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced the appointments of Lisa Pitt, Pharm.D., M.S.J. as Senior Vice President, Regulatory

14d agoYahoo Finance

Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

REDWOOD CITY, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced that management will participate at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026 in New York, NY. H.C. Wainwright 28th Annual Global Investment ConferencePresentation Date/Time: Wednesda

20d agoYahoo Finance

Jasper Therapeutics stock rating reiterated at Buy by H.C. Wainwright

1mo agoInvesting.com

Also Discussed

Investors talking about JSPR also mention

#	Name	Attention
1	AMAM - Ambrx Biopharma Inc.	——
2	American BriVision (Holding) CorporationABVC	0%+0
3	PBLA - Panbela Therapeutics, Inc.	——
4	ICVX - Icosavax, Inc.	——
5	SGMA - SigmaTron International, Inc.	——
6	Neurogene Inc.NGNE	0%0
7	EFTR - eFFECTOR Therapeutics, Inc.	——
8	Better Therapeutics, Inc.BTTX	0%new
9	FIAC - Focus Impact Acquisition Corp.	——
10	PALT - Paltalk, Inc.	——

Jasper Therapeutics, Inc.

Healthcare
Biotechnology

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for mast cell-driven and immune-mediated diseases. The company’s lead program, briquilimab, is a monoclonal antibody designed to target the CD117 pathway and reduce mast cell activity, supporting research in conditions such as chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics also works on hematopoietic stem cell-based approaches, including conditioning regimens intended to support stem cell transplantation and ex vivo gene therapy. Its current business is centered on clinical development, translational research, and advancing therapeutic candidates for patients with serious inflammatory, immunological, and transplant-related disorders. Headquartered in Redwood City, California, Jasper Therapeutics operates in the biotechnology sector and focuses on programs that aim to address high unmet medical needs through targeted biological therapies.

Website

Location

2200 Bridge Pkwy

Redwood City, CA, 94065

United States

Social

What share of all stock conversation is about JSPR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% +0	0% 0

Jul 17

Jasper Therapeutics has announced a merger with Kira Pharmaceuticals, combining their clinical pipelines and development resources, and is expected to be supported by a planned private placement of approximately $132 million.
The merger has been completed, and the combined company will continue trading on Nasdaq as JSPR, with common stock holders receiving a CVR worth around $1.5 payable when they receive a PRV by December 31, 2028.
Jasper's briquilimab, a potential treatment for SCID, may differentiate the company from Celldex's current indications, and the company plans to focus on other assets for now, with data expected at the end of the year.

Generated by AI

Sentiment

Of the messages about JSPR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% -100	52.87% -23.64
Bearish	—	—	100% new	47.13% +23.64

Bullish· Jul 17

The company has a strong pipeline, with three drug candidates and data expected end of year, which could lead to a significant increase in value.
The acquisition of Kira Pharma has extended the company's cash runway into 2028, providing a safety net and reducing the risk of future dilution.
The company's science and research are showing great promise, with a potential payout of $1.5 per share in 2028 and a new drug in phase 3, which could lead to a significant increase in value.

Bearish· Dec 3

The company's share price has experienced significant price destruction, with some users suggesting it's one of the "shittiest biotechs of all time".
The company's financial situation is uncertain, with some users expressing concern about dilution and the company's ability to raise more cash.
The company's product development is facing challenges, with some users questioning the effectiveness of their drug and suggesting the company is "incinerating investors".

Generated by AI

Topics

Of the messages about JSPR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	73.88%
Technical Analysis	—	—	—	11.42%
Analysts	—	—	—	7.79%
Controversies	—	—	—	0.87%
Earnings	—	—	—	2.6%
Macro	—	—	—	3.46%

Analysts· Oct 13

Oppenheimer analyst Jay Olson initiates coverage on Jasper Therapeutics with an Outperform rating and announces a price target of $21, viewing the company as an emerging leader in the development of novel targeted conditioning agents.
The analysts at Oppenheimer initiated coverage of Jasper Therapeutics with an Outperform rating and a $21 price target, citing the company's potential in hematopoietic stem cell transplantation.
Jasper Therapeutics shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target, implying a further 41% gain from current levels.

Announcements· Dec 2

Jasper Therapeutics ($JSPR) reports positive preliminary data from the ETESIAN study of Briquilimab in asthma, showing reductions in airway hyperresponsiveness and sputum eosinophils.
The company completed an internal investigation of the BEACON study with no issues found in the drug product, supporting further development of Briquilimab in asthma.
Jasper Therapeutics plans to host a conference call and webinar to discuss the positive preliminary data from the ETESIAN study and the findings from the BEACON study internal investigation.

Technical Analysis· Jan 13

$JSPR broke out higher after a pullback, reaching a high of $2.85 before selling off to flat.
The stock has resistance at $2.28 and $2.34, and may make a run if it can clear these levels.
$JSPR has a bullish reversal doji on the chart, and may be setting up for a cup and handle formation.

Generated by AI

Community

Of the messages about JSPR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	12.37%	38.45%
Newcomers	—	0%	87.63%	61.55%

Regulars· Jul 17

Jasper Therapeutics has finalized an all-stock acquisition of Kira Pharmaceuticals, establishing a robust immunology-focused biologics pipeline.
The company's strategic move is expected to extend its cash runway through 2028, with no more risk for cash until then, which is considered great.
Buyers are treating every pause in the stock's price as temporary, and the implied value for JSPR is around $0.70 per share, with the current price at $0.90.

Newcomers· Jul 17

The merger between Jasper Therapeutics and Kira Pharmaceuticals is expected to be supported by a private placement of approximately $132M via non-voting convertible preferred stock.
The combined company will trade on Nasdaq as JSPR, and common stock holders will receive a CVR worth around $1.5 payable when they receive a PRV by December 31, 2028.
Jasper Therapeutics has three drug candidates in development, with data expected at the end of the year, which may lead to a stock price surge.

Generated by AI

Jasper Therapeutics

Social

Jul 17

Bullish· Jul 17

Bearish· Dec 3

Analysts· Oct 13

Announcements· Dec 2

Technical Analysis· Jan 13

Regulars· Jul 17

Newcomers· Jul 17

Jasper Therapeutics announces CFO resignation and interim appointments

Jasper Therapeutics at H.C. Wainwright: cash and catalysts

Jasper Therapeutics appoints two executives to key roles

Jasper Therapeutics Announces Key Regulatory and Clinical Appointments

Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Jasper Therapeutics stock rating reiterated at Buy by H.C. Wainwright

Also Discussed

Jasper Therapeutics, Inc.

Company Information

Location

Jasper Therapeutics announces CFO resignation and interim appointments

Jasper Therapeutics at H.C. Wainwright: cash and catalysts

Jasper Therapeutics appoints two executives to key roles

Jasper Therapeutics Announces Key Regulatory and Clinical Appointments

Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Jasper Therapeutics stock rating reiterated at Buy by H.C. Wainwright

Also Discussed

Social

Jul 17

Bullish· Jul 17

Bearish· Dec 3

Analysts· Oct 13

Announcements· Dec 2

Technical Analysis· Jan 13

Regulars· Jul 17

Newcomers· Jul 17